AUTHORS
Jessica Leonard I, M.D., Andy Kaempf, MS2, Jessica Maria Stempel, MD, MHS3, Curtis Lachowiez, MD4, Elie Traer, MD, PhD5, Arpita Gandhi, M.D., M.S.6, Jennifer Saultz, DO7, Amrita Desai, MD,MPH8, Richard Thomas Maziarz, MD9, Daniel Chandra, MD10, Jean Sabile, MD11, Rachel Cook, M.D.12, Gabrielle Meyers, M.D.13, Tess Allen, BS, BA, MT(ASCP)14, Brandon Hayes-Lattin, M.D. FACP15, Ronan Swords, MD16
AFFILIATIONS
1 Oregon Health & Science University, Portland, Oregon, United States
2 Oregon Health & Science University, Portland, Oregon, United States
3 Oregon Health & Science University, Portland, Oregon, United States
4 Oregon Health & Science University, Portland, Oregon, United States
5 Oregon Health & Science University, Portland, Oregon, United States
6 Oregon Health & Science University, Portland, Oregon, United States
7 Oregon Health & Science University, Portland, Oregon, United States
8 Oregon Health & Science University, Portland, Oregon, United States
9 Oregon Health & Science University, Portland, Oregon, United States
10 Oregon Health & Science University, Portland, Oregon, United States
11 Oregon Health & Science University, Portland, Oregon, United States
12 Oregon Health & Science University, Portland, Oregon, United States
13 Oregon Health & Science University, Portland, Oregon, United States
14 Oregon Health & Science University, Portland, Oregon, United States
15 Oregon Health & Science University, Portland, Oregon, United States
16 Oregon Health & Science University, Portland, Oregon, United States
ABSTRACT
Introduction:
The second-generation ABL tyrosine kinase inhibitor dasatinib (Das) has shown impressive response rates in patients (pts) with Ph+ ALL, particularly when used in combination with immunotherapy (Foa NEJM 2020). However, acquired ABL mutations remain an important mechanism of treatment resistance and relapse. Venetoclax (Ven), a selective BCL-2 inhibitor, demonstrates synergistic activity with Das in preclinical models of Ph+ ALL (Leonard Sci Transl Med 2016). We conducted a phase 1b study evaluating the safety, tolerability and preliminary efficacy of Ven combined with Das, prednisone and blinatumomab in adults with newly diagnosed Ph+ ALL.
Methods:
This investigator-initiated phase 1b trial (NCT04872790) enrolled adults (≥18 years) with newly diagnosed Ph+ ALL or CML in lymphoid blast phase. Ven dose escalation followed a modified toxicity probability interval design to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). In cohorts of 3, patients were assigned to varying Ven dose levels (DLs): DL-1 = 100mg daily Day (D) 1-28; DL1 = 200mg daily D1-28; DL2 = 400mg daily D1-21 of a 28D cycle; DL3 = 400mg daily D1-28. Ven started on D3 in C1 with a 1-day ramp-up for DL2 and DL3. All pts received Das 140mg daily (100mg if ≥60 yrs), prednisone 2mg/kg (max of 120mg daily on D1-21, tapered off by D28), intrathecal methotrexate x 12, and rituximab (for CD20+ ALL). After 6 pts were enrolled, a protocol amendment introduced four cycles of blinatumomab (Blina) given for 4 weeks on, 2 weeks off starting after cycle 3 of induction. Ven and Das continued during Blina consolidation and afterwards until pts reached 12 months of total treatment, after which they continued Das monotherapy. Primary endpoints were dose-limiting toxicities (DLTs) and treatment-related adverse events (TAEs). Secondary endpoints included complete remission (CR), measurable residual disease (MRD) negativity by BCR::ABL PCR and next-generation sequencing (ClonoSEQ) at the end of induction, event-free survival (EFS), and overall survival (OS). Pts could discontinue study therapy at any time to undergo allogeneic hematopoietic stem cell transplant (alloHSCT) per physician discretion.
Results:
As of July 2026, all 20 enrolled pts completed induction. Median age was 51 years (range, 22–85), 45% were female, median white blood cell count at diagnosis was 12 × 10⁹/L (range, 0.5–483), and 25% had central nervous system involvement. Twenty-five percent of patients expressed the p210 BCR::ABL1 transcript, 60% the p190 ,15% both isoforms and 20% had an IKZF1-plus genotype.
Eighteen patients were evaluable for dose escalation. No dose-limiting toxicities were observed, and dose level 3 (Ven 400 mg daily, days 1–28) was identified as the RP2D.
The CR rate at day 28 was 100%; 10 pts (50%) achieved undetectable BCR::ABL PCR transcripts and 13 (65%) achieved MRD negativity by NGS. Among the 18 patients who completed all 3 cycles of induction, the end-of-induction MRD negativity was 61% by BCR-ABL PCR and 77% by NGS. At a median follow-up of 16 months, the estimated 1-year EFS and OS were 84% (95 % CI 69-100%) and 89% (95% CI 77-100%), respectively. Three of four patients with the IKZF1 signature remain in remission. There have been three deaths, two off treatment and one patient who elected hospice. There have been two relapses, one patient at DL1 with the IKZF1 phenotype and one patient at DL3 with a WBC count >100k at diagnosis. Eight patients proceeded to allo HSCT; 5 as institutional SOC, two for persistent MRD and one for relapsed disease.
Grade ≥3 treatment-related adverse events occurred in 12 patients (60%), predominantly hematologic toxicities. Five patients (25%) experienced treatment-related serious adverse events, including three pleural effusions, one enterocolitis, and one subdural hemorrhage related to treatment and/or procedure. Most serious adverse events were attributed to Das, and no unexpected safety signals were observed.
Conclusions:
The combination of Das and Ven was safe and well tolerated, with no dose-limiting toxicities observed and the RP2D of Ven was 400 mg daily. The regimen produced high complete remission rates, deep molecular responses and encouraging early survival outcomes, including in pts with the IKZF1-plus genotype. These findings support further evaluation of the combination of an ABL TKI and BCL-2 inhibitor in patients with newly diagnosed Ph+ ALL.
DISCLOSURES
Jessica Leonard I, M.D.: Takeda - Research Funding; AbbVie - Research Funding; KiTE - Consultancy (Includes expert testimony); Astra Zenica - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Adaptive Biotechnologies - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Pfeizer - Consultancy (Includes expert testimony); Autolus - Consultancy (Includes expert testimony)